论文部分内容阅读
Objective:The aim of our study was to observe the efficiency and toxicity of oxaliplatin (L-OHP) combined with CF/5-FU in patients with advanced primary hepatocellular carcinoma.Methods:Twenty patients with advanced primary hepatocellular carcinoma had recurrence/metastasis after multiple courses of TACE (cisplatin and epirubicin,etc.).All patients were treated with FOLFOX4 regimen of the combination of oxaliplatin and leucovorin and 5-fluorouracil.Treatment was repeated every 2 weeks until disease progression or unacceptable adverse effects occurred.The efficiency was evaluated according to RECIST criteria,and toxicities according to American National Cancer Institute Common Toxicity Criteria (NCI CTC),respectively.Results:Twenty patients were assessable for the objective efficiency and for toxicity.No patient achieved complete response (CR),4 patients were partial response (PR),8 patients were stable disease (SD),8 patients were disease progression (PD);Time to tumor progression (TTP) of the patients ranged from 1.5 to 4.8 months,median TTP was 2.2 months;Overall survival (OS) of the patients ranged from 3 to 10.2 months,median OS was 5 months.The 2 patients’ serum AFP level decreasing.Sixteen patients relieved the symptoms obviously,stabilized or raised up Karnofsky Score.The toxicities were mainly grade I-II arrest of bone marrow (50%),mild neurotoxicity (30%) and mild reaction of gastrointestinal tract (40%).Conclusion:FOLFOX4 regimen is effective and safe for patients with advanced primary hepatocellular carcinoma.It can be worthy of further clinical investigation.
Objective: The aim of our study was to observe the efficiency and toxicity of oxaliplatin (L-OHP) combined with CF / 5-FU in patients with advanced primary hepatocellular carcinoma. Methods: Twenty patients with advanced primary hepatocellular carcinoma had recurrence / metastasis after multiple courses of TACE (cisplatin and epirubicin, etc.). All patients were treated with FOLFOX4 regimen of the combination of oxaliplatin and leucovorin and 5-fluorouracil. Treatment was repeated every 2 weeks until disease progression or unacceptable. evaluated according to the American National Cancer Institute Common Toxicity Criteria (NCI CTC), respectively. Results: Twenty patients were assessable for the objective efficiency and for toxicity. No patient achieved complete response (CR), 4 patients were partial response (PR), 8 patients were stable disease (SD), 8 patients were disease progression (PD); Time to tumor progression (TTP ) of the patients ranged from 1.5 to 4.8 months, median TTP was 2.2 months; median survival was (OS) of the patients ranged from 3 to 10.2 months, median OS was 5 months. 2 patients’ serum AFP level decreasing the symptoms obviously, stabilized or raised up Karnofsky Score. toxicities were mainly grade I-II arrest of bone marrow (50%), mild neurotoxicity (30%) and mild reaction of gastrointestinal tract (40%). Conclusion: FOLFOX4 regimen is effective and safe for patients with advanced primary hepatocellular carcinoma. It can be worthy of further clinical investigation.